Progenabiome is starting two FDA-approved clinical trials that include hydroxychloroquine. One clinical trial is for the prevention of COVID. The second clinical trial is for the treatment of COVID.
"Many have called for clinical trials of hydroxychloroquine," said Dr. Sabine Hazan, CEO of Progenabiome, the Ventura-California-based genetic sequencing lab conducting the clinical trials. "We hope and expect these two clinical trials to provide definitive data on the efficacy of hydroxychloroquine for the prevention and treatment of COVID."
The prevention protocol includes a synergistic combination of HCQ, Vitamin C, Vitamin D, and Zinc. The treatment protocol will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Questions have been raised about hydroxychloroquine and heart complications. Cardiologist Alon Steinberg, Progenabiome's Chief Medical Officer, will screen and monitor patients for heart issues.
Dr. Hazan has been a practicing gastroenterologist and clinical trials investigator for over 25 years. She has participated in more than 150 clinical trials for the pharmaceutical and nutrition industries. Dr. Hazan launched Progenabiome in 2018 to investigate the role of the gut microbiome in various diseases and conditions.